BIOMAT Database Logo BIOMAT Database Logo

Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomized trial. 1990

G Steineck, and H Strander, and B E Carbin, and E Borgström, and L Wallin, and U Achtnich, and A Arvidsson, and V Söderlund, and I Näslund, and P L Esposti
Department of Oncology (Radiumhemmet), Karolinska Hospital, Stockholm, Sweden.

In a randomized study of advanced renal cell carcinoma 60 patients were allocated to treatment with either recombinant interferon alpha-2a or medroxyprogesterone acetate. Correlation between the dose of interferon alpha-2a and plasma-concentration indicated linear kinetics. Survival was similar in the two treatment groups. Only one complete and one partial response were seen in the interferon group and only one complete response in the medroxyprogesterone group, indicating a low therapeutic potential of both interferon and medroxyprogesterone. Interferon influenced the serum liver enzyme levels; increased transaminases were seen in 17 patients treated with interferon but in only four patients in the medroxyprogesterone group. Two patients had very high serum liver-enzyme levels concomitant with intolerable tiredness, in both patients the symptoms disappeared and the enzymes normalized after discontinuation of the interferon treatment. Antibodies to interferon developed frequently in patients receiving high dose oligomeric interferon therapy but rarely in patients receiving low dose monomeric interferon treatment.

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D007680 Kidney Neoplasms Tumors or cancers of the KIDNEY. Cancer of Kidney,Kidney Cancer,Renal Cancer,Cancer of the Kidney,Neoplasms, Kidney,Renal Neoplasms,Cancer, Kidney,Cancer, Renal,Cancers, Kidney,Cancers, Renal,Kidney Cancers,Kidney Neoplasm,Neoplasm, Kidney,Neoplasm, Renal,Neoplasms, Renal,Renal Cancers,Renal Neoplasm
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D008525 Medroxyprogesterone A synthetic progestational hormone used in veterinary practice as an estrus regulator. (6 alpha)-17-Hydroxy-6-methylpregn-4-ene-3,20-dione,Methylhydroxyprogesterone,Pregn-4-ene-3,20-dione, 17-hydroxy-6-methyl-, (6alpha)-,17 alpha-Hydroxy-6 alpha-Methylprogesterone,Adgyn Medro,17 alpha Hydroxy 6 alpha Methylprogesterone
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002292 Carcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma. Adenocarcinoma, Renal Cell,Carcinoma, Hypernephroid,Grawitz Tumor,Hypernephroma,Renal Carcinoma,Adenocarcinoma Of Kidney,Adenocarcinoma, Renal,Chromophil Renal Cell Carcinoma,Chromophobe Renal Cell Carcinoma,Clear Cell Renal Carcinoma,Clear Cell Renal Cell Carcinoma,Collecting Duct Carcinoma,Collecting Duct Carcinoma (Kidney),Collecting Duct Carcinoma of the Kidney,Nephroid Carcinoma,Papillary Renal Cell Carcinoma,Renal Cell Cancer,Renal Cell Carcinoma,Renal Cell Carcinoma, Papillary,Renal Collecting Duct Carcinoma,Sarcomatoid Renal Cell Carcinoma,Adenocarcinoma Of Kidneys,Adenocarcinomas, Renal Cell,Cancer, Renal Cell,Carcinoma, Collecting Duct,Carcinoma, Collecting Duct (Kidney),Carcinoma, Nephroid,Carcinoma, Renal,Carcinomas, Collecting Duct,Carcinomas, Collecting Duct (Kidney),Carcinomas, Renal Cell,Collecting Duct Carcinomas,Collecting Duct Carcinomas (Kidney),Hypernephroid Carcinoma,Hypernephroid Carcinomas,Hypernephromas,Kidney, Adenocarcinoma Of,Nephroid Carcinomas,Renal Adenocarcinoma,Renal Adenocarcinomas,Renal Carcinomas,Renal Cell Adenocarcinoma,Renal Cell Adenocarcinomas,Renal Cell Cancers,Renal Cell Carcinomas,Tumor, Grawitz
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

G Steineck, and H Strander, and B E Carbin, and E Borgström, and L Wallin, and U Achtnich, and A Arvidsson, and V Söderlund, and I Näslund, and P L Esposti
Phase II study of recombinant interferon alpha-2a and vinblastine in advanced renal cell carcinoma.
August 1989, The Journal of urology,
G Steineck, and H Strander, and B E Carbin, and E Borgström, and L Wallin, and U Achtnich, and A Arvidsson, and V Söderlund, and I Näslund, and P L Esposti
Recombinant leukocyte alpha interferon in advanced ovarian carcinoma.
January 1985, Cancer treatment reports,
G Steineck, and H Strander, and B E Carbin, and E Borgström, and L Wallin, and U Achtnich, and A Arvidsson, and V Söderlund, and I Näslund, and P L Esposti
Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma.
April 2001, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research,
G Steineck, and H Strander, and B E Carbin, and E Borgström, and L Wallin, and U Achtnich, and A Arvidsson, and V Söderlund, and I Näslund, and P L Esposti
Combination of recombinant interferon alpha-2a and vinblastine in advanced renal cell cancer.
December 1988, Cancer,
G Steineck, and H Strander, and B E Carbin, and E Borgström, and L Wallin, and U Achtnich, and A Arvidsson, and V Söderlund, and I Näslund, and P L Esposti
[Combination of recombinant interferon alpha-2A and vinblastine in advanced renal cell cancer].
October 1990, Onkologie,
G Steineck, and H Strander, and B E Carbin, and E Borgström, and L Wallin, and U Achtnich, and A Arvidsson, and V Söderlund, and I Näslund, and P L Esposti
Treatment of advanced renal cell cancer with recombinant interferon alpha as a single agent and in combination with medroxyprogesterone acetate. A randomized multicenter trial.
January 1988, Journal of cancer research and clinical oncology,
G Steineck, and H Strander, and B E Carbin, and E Borgström, and L Wallin, and U Achtnich, and A Arvidsson, and V Söderlund, and I Näslund, and P L Esposti
[Effect of recombinant alpha-interferon on advanced renal cell carcinoma].
December 1985, Hinyokika kiyo. Acta urologica Japonica,
G Steineck, and H Strander, and B E Carbin, and E Borgström, and L Wallin, and U Achtnich, and A Arvidsson, and V Söderlund, and I Näslund, and P L Esposti
Recombinant alpha-2a interferon plus vinblastine in the treatment of metastatic renal cell carcinoma.
February 1989, American journal of clinical oncology,
G Steineck, and H Strander, and B E Carbin, and E Borgström, and L Wallin, and U Achtnich, and A Arvidsson, and V Söderlund, and I Näslund, and P L Esposti
Recombinant interferon-alpha 2a and vinblastine in advanced renal cell cancer: a clinical phase I-II study.
August 1990, Journal of biological response modifiers,
G Steineck, and H Strander, and B E Carbin, and E Borgström, and L Wallin, and U Achtnich, and A Arvidsson, and V Söderlund, and I Näslund, and P L Esposti
Phase I trial of 5-fluorouracil and recombinant alpha 2a-interferon in patients with advanced colorectal carcinoma.
April 1990, Cancer research,
Copied contents to your clipboard!